Cantor Fitzgerald upgraded shares of Bradmer Pharmaceuticals (TSE:GLX – Free Report) to a strong-buy rating in a report published on Wednesday morning,Zacks.com reports.
Separately, HC Wainwright raised shares of Bradmer Pharmaceuticals to a “strong-buy” rating in a report on Thursday, October 10th.
View Our Latest Report on Bradmer Pharmaceuticals
Bradmer Pharmaceuticals Stock Performance
Featured Stories
- Five stocks we like better than Bradmer Pharmaceuticals
- The Most Important Warren Buffett Stock for Investors: His Own
- Starbucks’ CEO-Led Turnaround Gains Traction: New Highs Likely
- With Risk Tolerance, One Size Does Not Fit All
- 3 Chemical Stocks Defying Tariff Worries With Growth Potential
- Profitably Trade Stocks at 52-Week Highs
- How Growth Investors Find High-Growth Stocks and Maximize Returns
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
